V
Viva Vision Biotech
Viva Vision Biotech is a Healthcare Start Up Based In Shanghai
About Viva Vision Biotech
Viva Biotech Holdings (01873.HK) operates as a contract research organization (CRO) and contract development and manufacturing organization (CDMO), providing a comprehensive suite of services for the pharmaceutical and biotechnology sectors. Founded in 2008 by Cheney Mao, Feng Mao Hua, and Ying Wu, the Shanghai-based company has established itself as a key partner for global biopharmaceutical innovators. The firm's journey includes a significant milestone on May 9, 2019, when it successfully listed on the Hong Kong Stock Exchange, an IPO that was oversubscribed by more than 100 times, signaling strong investor confidence in its business model.
The company's business model is a hybrid, combining a conventional cash-for-service (CFS) structure with a distinctive equity-for-service (EFS) model. Under the CFS model, Viva Biotech generates revenue by providing a wide array of drug discovery and development services. These services span from the early stages of target identification, protein expression, and structure-based drug design to later-stage medicinal chemistry, and API (Active Pharmaceutical Ingredient) development and manufacturing through its subsidiary, Langhua Pharma. The company serves a global client base that includes nine of the top ten largest pharmaceutical companies.
Through its EFS model, managed by its investment arm Viva BioInnovator, the company invests in high-potential, early-stage biotechnology startups by providing its discovery services in exchange for equity. This approach allows Viva to build a diverse portfolio of investments in innovative drug development projects, creating long-term value while supporting emerging companies. As of December 2022, the company had invested in 91 portfolio companies, primarily located in North America and China. Viva Biotech has expanded its technological capabilities over the years, incorporating advanced platforms such as Cryo-Electron Microscopy (Cryo-EM), affinity selection mass spectrometry (ASMS), and an AI-driven drug discovery platform launched in May 2025.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2019
- Employees
- 177
- Open positions
- None listed
- Dealroom signal
- 71.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Investment activity
- 4 companies, latest Jun 2021
- Capital deployed
- $91M
- Preferred round
- SERIES A
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jun 2023 | $210M | — | Temasek · Highlight Capital · True Light | ↗ |
| POST IPO EQUITY✓Other financing | May 2023 | $14M | $230M | Sheng Yuan Zhiben · ChiFortune Venture · V-Capital · VVB Fund | ↗ |
Growth signals
Latest recorded traffic for Viva Vision Biotech is 4.6K monthly website visits, up 109.1% over the last three months. Viva Vision Biotech's team grew 3.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Forkhead BioTherapeuticsNew York City, United StatesForkhead BioTherapeutics is a biotechnology company
→
Triumvira ImmunologicsAustin, United StatesAt Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease
$275Mvaluation
Regenacy PharmaceuticalsWaltham, United StatesDeveloping ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies
$37Mvaluation
QurAlisCambridge, United StatesBiotech company focused on developing precision solutions to cure amyotrophic lateral sclerosis
$440Mvaluation
Viva Vision Biotech in the Huangpu ecosystem
The Viva Vision Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
JMCR Partners
Viva Ventures Biotech Fund
Series B and later15 investors entered at this stage
HSG
Cenova Capital- ZIZhongjince Investment
- BPBetta Pharmaceuticals
- XMXiamen Changrong Investment Management
- XRXizang Ruihai
- SGShenZhen GTJA Investment Group
- FIF&H Investment
- SZSheng Yuan Zhiben
- CVChiFortune Venture
V-Capital- VFVVB Fund
Temasek
Highlight Capital
True Light
Other known investors3 additional known investors
F&H Fund Management
Sequoia- SCShangyuan Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Viva Vision Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Viva Vision Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








